VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Bekaii-Saab Discusses an Analysis of Bevacizumab or Cetuximab for CRC

Tanios Bekaii-Saab, MD
Published: Thursday, Jul 24, 2014

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

This seven-year national trial compared bevacizumab and cetuximab in combination with FOLFOX and FOLFIRI for CRC. While previous studies have shown that the combination of bevacizumab/chemotherapy and the combination of cetuximab/chemotherapy both improve outcomes, the two agents have never been compared head to head. This study is the first study to compare bevacizumab and cetuximab head to head.

Results from this large trial suggest no difference in overall survival or progression-free survival. One complexity of this trial was that the chemotherapy was one of choice, Bekaii-Saab says. Researchers on this trial also hypothesize that FOLFIRI is a better backbone.

Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses an analysis of two targeted drugs for the treatment of patients with colorectal cancer (CRC).

This seven-year national trial compared bevacizumab and cetuximab in combination with FOLFOX and FOLFIRI for CRC. While previous studies have shown that the combination of bevacizumab/chemotherapy and the combination of cetuximab/chemotherapy both improve outcomes, the two agents have never been compared head to head. This study is the first study to compare bevacizumab and cetuximab head to head.

Results from this large trial suggest no difference in overall survival or progression-free survival. One complexity of this trial was that the chemotherapy was one of choice, Bekaii-Saab says. Researchers on this trial also hypothesize that FOLFIRI is a better backbone.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x